Ideally you would want a drug that inhibits Bach1 and also activates Nrf2.” To that end, Thomas partnered with the North Carolina-based company vTv Therapeutics to develop Bach1 inhibitors.

Ideally you would want a drug that inhibits Bach1 and also activates Nrf2." To that end, Thomas partnered with the North Carolina-based company vTv Therapeutics to develop Bach1 inhibitors.

Bach1 is involved in cellular stress pathways, and the regulation of another molecule called Nrf2. Nrf2 helps activate over 250 other genes that can protect cells from stress. Bach1 expression seems ...

Hence, the international research team designed new molecules that, besides inhibiting the BACH1 protein, activate the NRF2 protein. This protein controls the way that certain genes are expressed.

NRF2 is just one of thousands of critical proteins in the cell, but it is one that we now know a lot about. Once any molecule achieves a certain level of celebrity status, it tends to acquire a ...

Reduced expression of nuclear factor erythroid 2-related factor 2 (Nrf2) is observed in humans and animal models of Alzheimer’s disease (AD), with its activation being a promising therapeutic approach ...

IMMvention partners with Novo Nordisk to co-develop oral therapies for sickle cell disease using BACH1 inhibitors. Novo Nordisk to handle further development, regulatory, and commercialization ...

Lung cancer cells use antioxidants, endogenous or dietary, to spread in the body by activating a protein called BACH1 and increasing the uptake and use of sugar, researchers report in two ...

Other companies have hit on the idea of treating sickle cell by inhibiting BACH1. Mitobridge, which Astellas acquired for $225 million upfront in 2017, discovered the BACH1 inhibitor ML-0207, also ...

A new method than enables researchers to dial up or tone down the amount of a certain metastatic protein inhibitor (BACH1) within a cell could provide a new path in cancer research that reassesses ...

Nrf2 overexpression or Keap1 knockdown in glioma cells accelerate proliferation and oncogenic transformation. Further, activation of the Nrf2-Keap1 signaling upregulates xCT ...